Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: In fairness...

In fairness, we should remember that Directors and Officers of a Public Company need to be cautious in what they do and do not say to the public, including shareholders.

As TPL is not public Leckrone is not similarly constrained, and so his comments about things "will be better" for MMP (at least for TPL and implicitly for PTSC) may be words the BOD would like to have spoken but are constrained not to.

Both, however, are constrained by any non-disclosure or confidentiality clauses in licenses, agreements etc.

We did, however, hear that the CoMag was not modified as a result of settling the litigation against TPL and that the (or "a") related "obstacle" that the settlement removed was the lawsuit itself - which was apparently hampering negotiations with prospective licensees.

Share
New Message
Please login to post a reply